trending Market Intelligence /marketintelligence/en/news-insights/trending/Y39SAAdeRYhHqJoQTAYA1Q2 content esgSubNav
In This List

US FDA approves expanded efficacy claim for Zimmer's knee pain drug

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


US FDA approves expanded efficacy claim for Zimmer's knee pain drug

The U.S. FDA approved an expanded 26-week efficacy claim for Zimmer Biomet Holdings Inc.'s Gel-One Cross-linked Hyaluronate for the treatment of knee pain associated with osteoarthritis.